Stock Analysts’ Updated EPS Estimates for March, 15th (BXEFF, CANG, CARA, CCXI, CDAY, CICOY, CLNE, CLSD, CMFN, COT)

Stock Analysts’ updated eps estimates for Friday, March 15th:

Bellatrix Exploration (OTCMKTS:BXEFF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Bellatrix Exploration Ltd. is an oil and gas company engaged in the exploration for, and the acquisition, development and production of oil and natural gas reserves in the provinces of Alberta, British Columbia and Saskatchewan. Bellatrix Exploration Ltd. is headquartered in Calgary, Canada. “

Cango (NYSE:CANG) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cango Inc. provides an automotive transaction service platform which connects dealers, financial institutions, car buyers and other industry participants primarily in China. It offer automotive financing services which include facilitating financing transactions from financial institutions to car buyers; automotive transactions between automotive wholesalers, dealers, car buyers and after-market services to car buyers. Cango Inc. is headquartered in Shanghai, the People’s Republic of China. “

Cara Therapeutics (NASDAQ:CARA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. “

ChemoCentryx (NASDAQ:CCXI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “

Ceridian HCM (NYSE:CDAY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $56.00 price target on the stock. According to Zacks, “Ceridian HCM Holding Inc. provides human capital management software company. It provides human resources, payroll, benefits, workforce management and talent management functionality. Ceridian HCM Holding Inc. is based in Minneapolis, United States. “

COSCO SHIPPING/ADR (OTCMKTS:CICOY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $2.25 target price on the stock. According to Zacks, “China COSCO Holdings Company Limited is engaged in providing container shipping, dry bulk shipping, logistics services, terminal and container leasing for both international and domestic customers. The company engages in the management and operation of container terminals; provision of integrated logistics services, including third party logistics shipping agency and freight forwarding; and container manufacturing business. China COSCO Holdings Company Limited is based in Tianjin, the People’s Republic of China. “

Clean Energy Fuels (NASDAQ:CLNE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “CLEAN ENERGY FUELS, based in Seal Beach, Calif., is the leading provider of natural gas (CNG and LNG) for transportation in North America. It has a broad customer base in the refuse, transit, ports, shuttle, taxi, intrastate and interstate trucking, airport and municipal fleet markets,across the United States and Canada. “

Clearside Biomedical (NASDAQ:CLSD) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. “

CM Finance (NASDAQ:CMFN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $8.75 price target on the stock. According to Zacks, “CM Finance Inc. is an externally managed, closed-end, non-diversified management investment company. It invests primarily in middle-market companies in the U.S. The company invest through unitranche loans and standalone second and first lien loans with an emphasis on floating rate debt as well as in mezzanine loans/structured equity and in the equity of portfolio companies. CM Finance Inc. is based in New York, United States. “

Cott (NYSE:COT) (TSE:BCB) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Cott Corporation is a North American and European water, coffee and coffee extracts, tea and filtration solutions service company. “

Coupa Software (NASDAQ:COUP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Coupa Software Inc. provides cloud-based spend management platform which connects organizations with suppliers. Coupa Software Inc. is based in SAN MATEO, United States. “

CTS (NYSE:CTS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CTS Corporation is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components and supplies these products to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets. CTS focus on providing advanced technology, exceptional customer service and superior value to industry partners throughout the globe. CTS aims to be at the forefront of technology, delivering innovative sensing, connectivity and motion solutions for the creation and advancement of products and services around the world. CTS Corporation engages in the design, manufacture, assembly, and sale of electronic components and sensors, as well as the provision of electronics manufacturing services worldwide. It operates in two segments, Electronics Manufacturing Services, and Components and Sensors. “

Commercial Vehicle Group (NASDAQ:CVGI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $9.00 target price on the stock. According to Zacks, “Commercial Vehicle Group supplies interior systems, vision safety solutions and other cab-related products for the global commercial vehicle market, including the heavy-duty (Class 8) truck market, the construction market and other specialized transportation markets. The company’s products include suspension seat systems, interior trim systems, such as instrument and door panels, headliners, cabinetry and floor systems, mirrors, wiper systems, controls and switches specifically designed for applications in commercial vehicle cabs. “

CytoDyn (OTCMKTS:CYDY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $0.50 target price on the stock. According to Zacks, “CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. “

Dropbox (NASDAQ:DBX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $25.00 target price on the stock. According to Zacks, “Dropbox, Inc. is a service company. It offers a platform which enables users to store and share files, photos, videos, songs and spreadsheets. Dropbox, Inc. is headquartered in San Francisco, California. “

Receive News & Ratings for Bellatrix Exploration Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellatrix Exploration Ltd and related companies with MarketBeat.com's FREE daily email newsletter.